JP2018526033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526033A5 JP2018526033A5 JP2018532485A JP2018532485A JP2018526033A5 JP 2018526033 A5 JP2018526033 A5 JP 2018526033A5 JP 2018532485 A JP2018532485 A JP 2018532485A JP 2018532485 A JP2018532485 A JP 2018532485A JP 2018526033 A5 JP2018526033 A5 JP 2018526033A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- cancer
- cell
- dysfunctional
- chimeric antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 74
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 55
- 102000005962 receptors Human genes 0.000 claims description 55
- 108020003175 receptors Proteins 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 30
- 239000000427 antigen Substances 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 108020004707 nucleic acids Proteins 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 8
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 8
- 108091008034 costimulatory receptors Proteins 0.000 claims description 8
- 230000003213 activating effect Effects 0.000 claims description 5
- 150000001413 amino acids Chemical group 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 108010087819 Fc receptors Proteins 0.000 claims description 4
- 102000009109 Fc receptors Human genes 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 102100027207 CD27 antigen Human genes 0.000 claims description 3
- 101150013553 CD40 gene Proteins 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 3
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 201000004228 ovarian endometrial cancer Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000006134 tongue cancer Diseases 0.000 claims description 2
- 230000004068 intracellular signaling Effects 0.000 claims 2
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 239000012634 fragment Substances 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 102000013691 Interleukin-17 Human genes 0.000 description 5
- 108050003558 Interleukin-17 Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 108090000172 Interleukin-15 Proteins 0.000 description 3
- 108010002586 Interleukin-7 Proteins 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102100037602 P2X purinoceptor 7 Human genes 0.000 description 1
- 101710189965 P2X purinoceptor 7 Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021164222A JP7253020B2 (ja) | 2015-09-11 | 2021-10-05 | キメラ抗原受容体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015903719 | 2015-09-11 | ||
| AU2015903719A AU2015903719A0 (en) | 2015-09-11 | Chimeric antigen receptor and uses thereof | |
| PCT/AU2016/050851 WO2017041143A1 (en) | 2015-09-11 | 2016-09-10 | Chimeric antigen receptors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021164222A Division JP7253020B2 (ja) | 2015-09-11 | 2021-10-05 | キメラ抗原受容体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526033A JP2018526033A (ja) | 2018-09-13 |
| JP2018526033A5 true JP2018526033A5 (enExample) | 2020-09-10 |
| JP6957471B2 JP6957471B2 (ja) | 2021-11-02 |
Family
ID=58240468
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532485A Active JP6957471B2 (ja) | 2015-09-11 | 2016-09-10 | キメラ抗原受容体およびその使用 |
| JP2021164222A Active JP7253020B2 (ja) | 2015-09-11 | 2021-10-05 | キメラ抗原受容体およびその使用 |
| JP2023047606A Active JP7822340B2 (ja) | 2015-09-11 | 2023-03-24 | キメラ抗原受容体およびその使用 |
| JP2025052912A Pending JP2025098188A (ja) | 2015-09-11 | 2025-03-27 | キメラ抗原受容体およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021164222A Active JP7253020B2 (ja) | 2015-09-11 | 2021-10-05 | キメラ抗原受容体およびその使用 |
| JP2023047606A Active JP7822340B2 (ja) | 2015-09-11 | 2023-03-24 | キメラ抗原受容体およびその使用 |
| JP2025052912A Pending JP2025098188A (ja) | 2015-09-11 | 2025-03-27 | キメラ抗原受容体およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US12121539B2 (enExample) |
| EP (2) | EP3347474B1 (enExample) |
| JP (4) | JP6957471B2 (enExample) |
| KR (2) | KR20250058773A (enExample) |
| CN (2) | CN114891116A (enExample) |
| AU (4) | AU2016318230B2 (enExample) |
| ES (1) | ES2848478T3 (enExample) |
| WO (1) | WO2017041143A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3872094A3 (en) | 2014-12-05 | 2021-12-08 | Memorial Sloan Kettering Cancer Center | Antibodies targeting b-cell maturation antigen and methods of use |
| AU2016318230B2 (en) * | 2015-09-11 | 2020-05-21 | Biosceptre (Aust) Pty Ltd | Chimeric antigen receptors and uses thereof |
| PL233352B1 (pl) * | 2016-09-15 | 2019-10-31 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe białko fuzyjne |
| MX2020004572A (es) | 2017-11-01 | 2020-10-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos. |
| EP3706754A1 (en) | 2017-11-06 | 2020-09-16 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| CA3084445A1 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Process for producing a composition of engineered t cells |
| CA3086832A1 (en) | 2018-01-03 | 2019-07-11 | Qu Biologics Inc. | Innate targeting of adoptive cellular therapies |
| WO2019166453A1 (en) * | 2018-03-01 | 2019-09-06 | F. Hoffmann-La Roche Ag | Specificity assay for novel target antigen binding moieties |
| EP3765093A4 (en) * | 2018-03-15 | 2021-12-08 | Fundamental Solutions Corporation | PROGRAMMABLE IMMUNOCYTE RECEPTOR COMPLEX SYSTEM |
| CN112166193A (zh) * | 2018-05-21 | 2021-01-01 | 生物权威（英国）有限公司 | 具有经修饰的接头结构域的嵌合抗原受体及其用途 |
| CN110856724B (zh) * | 2018-08-24 | 2022-05-27 | 杭州康万达医药科技有限公司 | 包含核酸及car修饰的免疫细胞的治疗剂及其应用 |
| SG11202104188VA (en) | 2018-11-01 | 2021-05-28 | Juno Therapeutics Inc | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| US20220251187A1 (en) * | 2019-07-26 | 2022-08-11 | Biosceptre (Aust) Pty Ltd | P2x7 receptor targeted therapy |
| CA3211323A1 (en) * | 2021-03-11 | 2022-09-15 | Patrick Schlegel | Novel cell therapy system |
| AU2022341030A1 (en) * | 2021-09-01 | 2023-11-30 | Biosceptre (Aust) Pty Ltd | Methods and compositions for stimulating immune activity |
| JP2025531675A (ja) * | 2022-09-14 | 2025-09-25 | バイオセプター （オースト） プロプライエタリー・リミテッド | 操作された免疫細胞の富化 |
| JP2025531030A (ja) * | 2022-09-14 | 2025-09-19 | バイオセプター （オースト） プロプライエタリー・リミテッド | 免疫細胞のインビボ検出 |
| US20260085104A1 (en) * | 2022-09-14 | 2026-03-26 | Biosceptre (Aust) Pty Ltd | Methods of detecting immune cells |
| TW202525839A (zh) * | 2023-09-06 | 2025-07-01 | 美國加利福尼亞大學董事會 | 治療癌症之方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4940661A (en) | 1984-05-17 | 1990-07-10 | Genentech, Inc. | Metallothionein transcription control sequences and use thereof |
| US5512483A (en) | 1993-05-21 | 1996-04-30 | Mcgill University | Expression vectors responsive to steroid hormones |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| CZ372297A3 (cs) | 1995-05-26 | 1998-03-18 | Zeneca Limited | Přepínání genové exprese využívající receptoru pro ekdyson |
| US5851796A (en) | 1995-06-07 | 1998-12-22 | Yale University | Autoregulatory tetracycline-regulated system for inducible gene expression in eucaryotes |
| AUPP991199A0 (en) | 1999-04-21 | 1999-05-13 | University Of Sydney, The | Methods for diagnosing pre-cancerous and cancerous conditions |
| WO2001020155A1 (fr) | 1999-09-16 | 2001-03-22 | Liangqi Zhang | Membrane de reduction de pression pour carburateur |
| AUPQ968700A0 (en) | 2000-08-28 | 2000-09-21 | Intreat Pty Limited | Treatment of urinary incontinence |
| AUPR201500A0 (en) | 2000-12-11 | 2001-01-11 | Biosceptre Pty Ltd | Methods for identifying pre-neoplastic and neoplastic states in mammals |
| CA2434490C (en) | 2001-01-17 | 2014-06-03 | Intreat Pty Limited | Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions |
| US20030203411A1 (en) * | 2001-06-05 | 2003-10-30 | Sabbadini Roger A. | Methods of minicell-based delivery |
| NZ549019A (en) | 2001-09-03 | 2008-05-30 | Intreat Pty Ltd | Antibody that binds to a P2X7 receptor in which proline at position 210 is in a cis conformation |
| CA2402930A1 (en) * | 2002-09-19 | 2004-03-19 | William Herman | Targeted ligands |
| DK2330121T3 (en) | 2004-06-02 | 2014-12-15 | Adalta Pty Ltd | Binding moieties based on shark IgNar domains |
| US8067550B2 (en) | 2006-10-10 | 2011-11-29 | Biosceptre International Limited | Hybridomas producing antibodies against non functional P2X7 receptor |
| WO2008043146A1 (en) | 2006-10-10 | 2008-04-17 | Biosceptre International Limited | Antibodies against non functional p2x7 receptor |
| MX2010001684A (es) * | 2007-08-15 | 2010-04-21 | Amunix Inc | Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos. |
| CA2737126C (en) * | 2007-09-14 | 2018-05-01 | Biosceptre International Limited | Novel p2x7 epitopes |
| NZ583896A (en) | 2007-09-14 | 2011-05-27 | Biosceptre Int Ltd | Purinergic (p2x) receptors in extra-cellular body fluid |
| US8840186B2 (en) | 2007-11-07 | 2014-09-23 | L&P Swiss Holding Ag | Support assembly and corresponding seat structure |
| AU2009266430B2 (en) * | 2008-07-04 | 2014-08-14 | Biosceptre International Limited | Anti- P2X7 peptides and epitopes |
| JP5164806B2 (ja) | 2008-11-12 | 2013-03-21 | サンデン株式会社 | 車両用通信制御装置 |
| CN102858985A (zh) * | 2009-07-24 | 2013-01-02 | 西格马-奥尔德里奇有限责任公司 | 基因组编辑方法 |
| JP5936067B2 (ja) * | 2009-08-20 | 2016-06-15 | バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド | 抗ｐ２ｘ７受容体抗体およびその断片 |
| BR112012015561B1 (pt) | 2009-12-24 | 2019-11-12 | Biosceptre International Limited | anticorpos dirigidos contra receptores p2x7 oligoméricos não funcionais |
| WO2012031333A1 (en) | 2010-09-10 | 2012-03-15 | Biosceptre International Limited | Companion animal treatments |
| US20140154241A1 (en) | 2010-12-03 | 2014-06-05 | Cyclogenix Ltd | Binding peptides i |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP3693017A1 (en) | 2010-12-14 | 2020-08-12 | University of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| BR112013033974A2 (pt) | 2011-07-01 | 2017-02-14 | Biosceptre Int Ltd | terapia de combinação |
| WO2014055657A1 (en) * | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AU2015216875B2 (en) * | 2014-02-14 | 2021-02-25 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| CA2969704C (en) | 2014-12-05 | 2023-05-02 | City Of Hope | Cs1 targeted chimeric antigen receptor-modified t cells |
| EP3250611B1 (en) | 2015-01-26 | 2021-04-21 | The University of Chicago | Car t-cells recognizing cancer-specific il 13r-alpha2 |
| CN107614528A (zh) | 2015-04-02 | 2018-01-19 | 生物权威（英国）有限公司 | 疼痛治疗 |
| AU2016318230B2 (en) | 2015-09-11 | 2020-05-21 | Biosceptre (Aust) Pty Ltd | Chimeric antigen receptors and uses thereof |
| CN109310764B (zh) | 2016-04-15 | 2022-01-14 | 达特茅斯大学理事会 | 高亲和力b7-h6抗体和抗体片段 |
| WO2018017649A1 (en) | 2016-07-19 | 2018-01-25 | Unum Therapeutics Inc. | Use of antibody-coupled t cell receptor (actr) with multiple anti-cancer antibodies in cancer treatment |
| WO2018064626A1 (en) | 2016-09-30 | 2018-04-05 | Baylor College Of Medicine | Adaptive chimeric antigen receptor t-cell design |
| CN109862883A (zh) | 2016-10-21 | 2019-06-07 | 生物权威（英国）有限公司 | 细胞毒性颗粒 |
| CN112166193A (zh) | 2018-05-21 | 2021-01-01 | 生物权威（英国）有限公司 | 具有经修饰的接头结构域的嵌合抗原受体及其用途 |
| US20220251187A1 (en) | 2019-07-26 | 2022-08-11 | Biosceptre (Aust) Pty Ltd | P2x7 receptor targeted therapy |
-
2016
- 2016-09-10 AU AU2016318230A patent/AU2016318230B2/en active Active
- 2016-09-10 WO PCT/AU2016/050851 patent/WO2017041143A1/en not_active Ceased
- 2016-09-10 ES ES16843305T patent/ES2848478T3/es active Active
- 2016-09-10 US US15/759,046 patent/US12121539B2/en active Active
- 2016-09-10 EP EP16843305.0A patent/EP3347474B1/en active Active
- 2016-09-10 KR KR1020257012877A patent/KR20250058773A/ko active Pending
- 2016-09-10 KR KR1020187010203A patent/KR20180043841A/ko not_active Ceased
- 2016-09-10 EP EP20197564.6A patent/EP3816294A1/en active Pending
- 2016-09-10 JP JP2018532485A patent/JP6957471B2/ja active Active
- 2016-09-10 CN CN202210429775.5A patent/CN114891116A/zh active Pending
- 2016-09-10 CN CN201680064592.0A patent/CN108350462B/zh active Active
-
2020
- 2020-07-28 AU AU2020210185A patent/AU2020210185C1/en active Active
- 2020-10-23 US US17/078,969 patent/US20210038649A1/en not_active Abandoned
-
2021
- 2021-10-05 JP JP2021164222A patent/JP7253020B2/ja active Active
-
2022
- 2022-02-24 AU AU2022201263A patent/AU2022201263B2/en active Active
-
2023
- 2023-03-24 JP JP2023047606A patent/JP7822340B2/ja active Active
-
2024
- 2024-07-24 US US18/783,109 patent/US20250101080A1/en active Pending
- 2024-08-07 AU AU2024205598A patent/AU2024205598B2/en active Active
-
2025
- 2025-03-27 JP JP2025052912A patent/JP2025098188A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7737440B2 (ja) | 抗ヒトパピローマウイルス（ｈｐｖ）抗原結合性タンパク質およびその使用方法 | |
| TWI809130B (zh) | 嵌合跨膜蛋白及其用途 | |
| CN108884164B (zh) | 用于免疫疗法的经修饰细胞 | |
| EP3472205B1 (en) | Chimeric antigen receptor | |
| JP2018529327A5 (enExample) | ||
| CN114391021B (zh) | TGF-β受体和使用方法 | |
| CN113646335A (zh) | 使用对b细胞成熟抗原具有特异性的嵌合抗原受体的治疗的方法 | |
| JP2018528786A5 (enExample) | ||
| CN115403671A (zh) | 靶向Claudin18.2的纳米抗体及其用途 | |
| CN110678480A (zh) | 嵌合多肽和改变它们的在细胞膜中的定位的方法 | |
| JP2025536940A (ja) | 新規ｃｄ１９バインダー、それを含むｃａｒ－ｔ構造体、およびその使用方法 | |
| CN117677633A (zh) | 基于nkg2d的嵌合抗原受体 | |
| TWI849430B (zh) | Ｇｐｃ３結合分子 | |
| KR20230124656A (ko) | 전립선암 키메라 항원 수용체 | |
| US20250297282A1 (en) | Viral-binding protein and related reagents, articles, and methods of use | |
| CN112279915A (zh) | Icos抗体、基因、载体、宿主细胞和icos拮抗剂 | |
| HK40072388A (zh) | TGF-β受体和使用方法 | |
| JP2026082962A (ja) | キメラ抗原受容体 | |
| KR20230172002A (ko) | Taci/bcma 이중 결합 분자 | |
| WO2024210072A1 (ja) | キメラタンパク質、核酸、ベクター、ｔ細胞又はｎｋ細胞、医薬組成物、組み合わせ物、組み合わせ医薬、及び標的抗原結合タンパク質 | |
| JP2025539151A (ja) | Ｌｉｌｒｂ４を特異的に結合する合成ｔ細胞受容体抗原受容体およびその使用 | |
| HK40072388B (zh) | TGF-β受体和使用方法 | |
| CN117586411A (zh) | 一种结合tnfr2和ccr8的双特异性抗体 | |
| CN120225549A (zh) | 对b细胞成熟抗原(bcma)和/或跨膜激活剂和caml相互作用因子(taci)具有特异性的嵌合抗原受体 | |
| EA040856B1 (ru) | Белки, связывающие лиганд 1 запрограммированной смерти 1 (pd-l1), и способы их использования |